Publications
Publications
Show Results For
-
All HBS Web
(112,695)
- Faculty Publications (48)
Page 1 of
48
Results
→
- July 2023
- Supplement
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
This spreadsheet supplement corresponds to Exhibit 17 (Change in Biogen Valuation from Aducanumab Approval) from Case 623-046 "Biogen and the Aduhelm Melee."
View Details
- June 2023
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This case...
View Details
- June 2023
- Supplement
Ishani Therapeutics: Valuing a Deal (Instructor Spreadsheet Supplement)
By: Amitabh Chandra and Sumon Mazumdar
- June 2023
- Supplement
Ishani Therapeutics: Valuing a Deal (Student Spreadsheet Supplement)
By: Amitabh Chandra and Sumon Mazumdar
- April 2023
- Case
Elliott Management: Capital Allocation in Biopharma
By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an...
View Details
- January 2023
- Case
Vertex and the Cure for Type 1 Diabetes
By: Amitabh Chandra, William J Anderson and Silvia Mare
Keywords:
Biotechnology Industry
- 2023
- Working Paper
Achieving Universal Health Insurance Coverage in the United States: Addressing Market Failures or Providing a Social Floor?
By: Katherine Baicker, Amitabh Chandra and Mark Shepard
The United States spends substantially more on health care than most developed countries, yet leaves a greater share of the population uninsured. We suggest that incremental insurance expansions focused on addressing market failures will propagate inefficiencies and...
View Details
- 2022
- Working Paper
Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation
By: Amitabh Chandra, Jennifer Kao, Kathleen Miller and Ariel D. Stern
Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA’s Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to...
View Details
- July 2022
- Supplement
Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A (Spreadsheet Supplement)
By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
- July 2022
- Teaching Note
Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A
By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
Teaching Note for HBS Case No. 622-075.
View Details
- January 2022 (Revised July 2022)
- Case
Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A
By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
- December 2021 (Revised February 2023)
- Teaching Note
Value-Based Insurance Design at Onex
By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal
Teaching Note for HBS Case No. 921-023.
View Details
- Article
Supporting Value-Based Health Care—Aligning Financial and Legal Accountability
By: Mark M. Zaki, Anupam B. Jena and Amitabh Chandra
U.S. health care payment and delivery-system reforms have focused on improving care by making organizations accountable for outcomes, quality, and costs. Payers have supported the implementation of accountable care organizations (ACOs), bundled-payment models, and...
View Details
- June 2021
- Case
Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (A)
By: Amitabh Chandra and Spencer Lee-Rey
- June 2021
- Supplement
Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)
By: Amitabh Chandra and Spencer Lee-Rey
- 2021
- Working Paper
Regulatory Approval and Expanded Market Size
By: Benjamin Berger, Amitabh Chandra and Craig Garthwaite
Regulatory review of new medicines is often viewed as a hindrance to innovation by increasing the hurdle to bring products to market. However, a more complete accounting of regulation must also account for its potential market expanding effects through quality...
View Details
- 2021
- Working Paper
The Great Unequalizer: Initial Health Effects of COVID-19 in the United States
By: Marcella Alsan, Amitabh Chandra and Kosali I. Simon
We measure inequities from the COVID-19 pandemic on mortality and hospitalizations in the United States during the early months of the outbreak. We discuss challenges in measuring health outcomes and health inequality, some of which are specific to COVID-19 and others...
View Details
- May 2021
- Case
The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease
By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory...
View Details
- 2021
- Working Paper
The Health Costs of Cost-Sharing
By: Amitabh Chandra, Evan Flack and Ziad Obermeyer
We use the design of Medicare’s prescription drug benefit program to demonstrate three facts about the health consequences of cost-sharing. First, we show that an as-if-random increase of 33.6% in out-of-pocket price (11.0 percentage points (p.p.) change in...
View Details